Naive CD4+T Cells Modified to Express a ROR1-Specific CAR Mediate Anti-Tumor Activity and Provide Superior Help to CD8+ROR1-CAR T Cells

被引：0
|
作者：
Hudecek, Michael [1 ]
Lupo-Stanghellini, Maria-Teresa [1 ]
Kosasih, Paula [1 ]
Bet, Jeannette [1 ]
Paszkiewicz, Paulina [1 ]
Maloney, David G. [1 ]
Jensen, Michael C. [2 ]
Rader, Christoph [3 ]
Riddell, Stanley R. [1 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[2] Seattle Childrens Res Inst, Ctr Childhood Canc Res, Seattle, WA USA
[3] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：294 / 294
页数：1
相关论文
共 50 条
  • [31] CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells
    Yang, Yinmeng
    Lin, Tasha
    Jacoby, Elad
    Qin, Haiying
    Gardner, Elizabeth Grier
    Chien, Christopher Daniel
    Lee, Daniel W., III
    Fry, Terry J.
    BLOOD, 2015, 126 (23)
  • [32] The anti-tumor function of ROR1-CAR modified T-cells against triple-negative breast cancer is enhanced by shielding from immunosuppressive TGF-β
    Stueber, T.
    Wallstabe, L.
    Rydzek, J.
    Nerreter, T.
    Woeckel, A.
    Einsele, H.
    Wischhusen, J.
    Hudecek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 7 - 7
  • [33] Unedited CD7 CAR T-Cells Overcome Fratricide and Produce Superior Anti-Tumor Activity in a Preclinical Model of T-Cell Leukemia
    Watanabe, Norihiro
    Mo, Feiyan
    Ma, Royce
    Srinivasan, Madhuwanti
    McKenna, Mary K.
    Scherer, Lauren D.
    Mamonkin, Maksim
    MOLECULAR THERAPY, 2021, 29 (04) : 302 - 303
  • [34] Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
    Stuber, Tanja
    Monjezi, Razieh
    Wallstabe, Lars
    Kuehnemundt, Johanna
    Nietzer, Sarah Louise
    Dandekar, Gudrun
    Woeckel, Achim
    Einsele, Hermann
    Wischhusen, Joerg
    Hudecek, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [35] Ocular melanoma cells genetically modified to express HLA-DR and CD80 activate tumor-specific CD4+T cells
    Bosch, Jacobus J.
    Thompson, James A.
    Dissanayake, Samudra K.
    Ksander, Bruce R.
    Ostrand-Rosenberg, Suzanne
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S258 - S258
  • [36] TARGET THE ACTIVIN RECEPTOR 1C ON CD4+T CELLS TO ACHIEVE ANTI-TUMOR THERAPEUTIC EFFECTS
    Zheng, Ying
    Lebid, Andriana
    Pardoll, Andrew
    Fu, Juan
    Patel, Chirag
    Wang, Xiaoxu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A679 - A679
  • [37] Target the activin receptor 1c on CD4+T cells to achieve anti-tumor therapeutic effects
    Zheng, Ying
    Lebid, Andriana
    Fu, Juan
    Patel, Chirag
    Wang, Xiaoxu
    Pardoll, Drew
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [38] Cytotoxic CD4+T cells contribute to anti-tumor immune responses in NSCLC.
    Lau, Denise
    Khare, Sonal
    Reiman, Derek
    Rand, Tim
    Salahudeen, Ameen A.
    Khan, Aly
    CANCER RESEARCH, 2021, 81 (13)
  • [39] Memory Phenotype CD8+T Cells Are Superior to Naive CD8+T Cells in Separating Graft Anti-Tumor Activity From Gvhd After Bone Marrow Transplantation; Application to DLI.
    Dutt, Suparna
    Baker, Jeanette
    Kambham, Neeraja
    Kohrt, Holbrook E.
    Negrin, Robert
    Strober, Samuel
    BLOOD, 2009, 114 (22) : 967 - 967
  • [40] Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies
    Hill, LaQuisa C.
    Rouce, Rayne H.
    Smith, Tyler S.
    Yang, Lina
    Srinivasan, Madhuwanti
    Zhang, Huimin
    Perconti, Silvana
    Mehta, Birju
    Dakhova, Olga
    Randall, Josalind
    Grilley, Bambi J.
    Heslop, Helen E.
    Brenner, Malcolm K.
    Mamonkin, Maksim
    BLOOD, 2019, 134
12345